SAGE Therapeutics Announces Nasdaq Delisting After Merger

SAGE Therapeutics ( (SAGE) ) has shared an update.

On July 30, 2025, SAGE Therapeutics, a company involved in the biopharmaceutical industry, announced its decision to delist its shares from The Nasdaq Global Market. The company notified Nasdaq of the consummation of a merger and requested the suspension of trading and the filing of a Form 25 to delist and deregister its shares. Consequently, SAGE Therapeutics plans to terminate its common stock registration and suspend its reporting obligations. As part of the merger, the company’s board of directors and executive officers underwent significant changes. Several directors and officers resigned, and new directors and officers from the Purchaser assumed their roles. Additionally, the company amended severance agreements with its executive officers, enhancing severance benefits and extending non-compete covenants.

The most recent analyst rating on (SAGE) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on SAGE Therapeutics stock, see the SAGE Stock Forecast page.

Spark’s Take on SAGE Stock

According to Spark, TipRanks’ AI Analyst, SAGE is a Neutral.

The overall stock score for SAGE is influenced primarily by its challenging financial performance, which presents significant risks. Despite some positive momentum in technical analysis and a promising earnings call focused on growth for ZURZUVAE, the negative valuation highlights persistent profitability concerns. The announced merger with Supernus Pharmaceuticals provides a positive outlook, but the existing financial issues weigh heavily on the overall score.

To see Spark’s full report on SAGE stock, click here.

More about SAGE Therapeutics

Average Trading Volume: 2,449,892

Technical Sentiment Signal: Sell

Current Market Cap: $544.9M

For a thorough assessment of SAGE stock, go to TipRanks’ Stock Analysis page.